Abstract
Lorlatinib is an oral small molecule inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the trea......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
